Cerecor Inc (NASDAQ:CERC) major shareholder Armistice Capital Master Fund acquired 20,000 shares of Cerecor stock in a transaction dated Tuesday, May 14th. The stock was bought at an average price of $4.97 per share, with a total value of $99,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Armistice Capital Master Fund also recently made the following trade(s):
- On Wednesday, March 27th, Armistice Capital Master Fund acquired 50,000 shares of Cerecor stock. The stock was bought at an average price of $5.47 per share, with a total value of $273,500.00.
- On Friday, March 8th, Armistice Capital Master Fund acquired 374,486 shares of Cerecor stock. The stock was bought at an average price of $5.50 per share, with a total value of $2,059,673.00.
Shares of Cerecor stock opened at $5.29 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.91 and a current ratio of 0.95. Cerecor Inc has a fifty-two week low of $2.71 and a fifty-two week high of $7.65.
Cerecor (NASDAQ:CERC) last issued its earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $5.41 million during the quarter, compared to the consensus estimate of $4.85 million. Cerecor had a negative net margin of 226.50% and a negative return on equity of 120.67%. On average, equities analysts predict that Cerecor Inc will post -0.72 EPS for the current fiscal year.
CERC has been the subject of several analyst reports. Maxim Group restated a “buy” rating and issued a $10.00 price objective on shares of Cerecor in a research note on Friday, May 10th. ValuEngine lowered Cerecor from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Cerecor in a research note on Monday, April 29th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $9.00 target price on shares of Cerecor in a report on Thursday, January 17th. Finally, TheStreet raised shares of Cerecor from a “d” rating to a “c-” rating in a report on Wednesday, January 30th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.67.
A number of institutional investors have recently modified their holdings of CERC. Opaleye Management Inc. bought a new position in Cerecor in the 4th quarter worth $6,212,000. Prosight Management LP bought a new position in Cerecor in the 4th quarter worth $994,000. Tibra Equities Europe Ltd bought a new position in Cerecor in the 1st quarter worth $210,000. Geode Capital Management LLC boosted its holdings in Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock worth $306,000 after buying an additional 31,951 shares during the period. Finally, Spark Investment Management LLC boosted its holdings in Cerecor by 60.5% in the 1st quarter. Spark Investment Management LLC now owns 83,000 shares of the company’s stock worth $484,000 after buying an additional 31,290 shares during the period. 50.28% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://transcriptdaily.com/2019/05/16/cerecor-inc-cerc-major-shareholder-buys-99400-00-in-stock.html.
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Recommended Story: Is the QQQ ETF safe?
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.